Sandoval, J., Villy, M. C., Labidi-Galy, I., Callens, C., Popova, T., Blons, H., Quesada, S., Sehouli, J., Zamagni, C., Guerra, E., Schauer, C., Lindahl, G., Derio, S., Gorp, T. V., Fujiwara, K., Genestie, C., Pujade-Lauraine, E., Ray-Coquard, I. L., Rodrigues, M. (2025). Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): Phase III PAOLA-1 GINECO/ENGOT-ov25 trial exploratory analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5576